Published in Toxicol Sci on November 01, 2002
Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ Health Perspect (2006) 0.81
Cumulative Risk Assessment (CRA): transforming the way we assess health risks. Environ Sci Technol (2012) 0.78
Dispelling urban myths about default uncertainty factors in chemical risk assessment--sufficient protection against mixture effects? Environ Health (2013) 0.76
Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci (2011) 2.03
Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal (2007) 1.61
Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. Toxicol Sci (2008) 1.51
Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol Sci (2005) 1.35
Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. Toxicology (2006) 1.34
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci (2010) 1.30
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology (2010) 1.28
Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol (2006) 1.19
Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics? Environ Health Perspect (2013) 1.14
Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study. Toxicol Sci (2003) 1.12
Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci (2013) 1.10
Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. Environ Sci Technol (2005) 1.04
Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci (2013) 1.03
Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A (2006) 1.03
Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci (2010) 1.03
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A (2013) 1.00
A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci (2007) 1.00
Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. Toxicol Sci (2010) 0.99
Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol (2006) 0.98
Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology (2006) 0.98
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol Sci (2013) 0.98
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol (2008) 0.96
The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul Toxicol Pharmacol (2006) 0.96
Can case study approaches speed implementation of the NRC report: "toxicity testing in the 21st century: a vision and a strategy?". ALTEX (2011) 0.95
Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett (2007) 0.95
Copper and human health: biochemistry, genetics, and strategies for modeling dose-response relationships. J Toxicol Environ Health B Crit Rev (2007) 0.95
The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX (2012) 0.93
Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. Regul Toxicol Pharmacol (2007) 0.93
Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound. Toxicol Sci (2010) 0.93
Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol (2012) 0.93
Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci (2011) 0.92
Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. Mutat Res (2012) 0.92
Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein. Inhal Toxicol (2008) 0.91
Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol In Vitro (2009) 0.91
Making sense of human biomonitoring data: findings and recommendations of a workshop. J Expo Sci Environ Epidemiol (2007) 0.91
Physiologically based pharmacokinetic modeling of arsenic in the mouse. J Toxicol Environ Health A (2004) 0.90
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol (2003) 0.90
Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol (2007) 0.89
Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect (2015) 0.88
Role of the aryl hydrocarbon receptor in cell cycle regulation. Toxicology (2002) 0.88
Resources for global risk assessment: the International Toxicity Estimates for Risk (ITER) and Risk Information Exchange (RiskIE) databases. Toxicol Appl Pharmacol (2008) 0.88
Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ Mol Mutagen (2010) 0.88
The evolution of skin notations for occupational risk assessment: a new NIOSH strategy. Regul Toxicol Pharmacol (2011) 0.87
Pharmacokinetic modeling of manganese in the rat IV: Assessing factors that contribute to brain accumulation during inhalation exposure. J Toxicol Environ Health A (2008) 0.87
Hormesis and adaptive cellular control systems. Dose Response (2008) 0.86
Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci (2010) 0.86
Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J Toxicol Environ Health A (2007) 0.85
Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol Sci (2009) 0.85
Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. Toxicol Sci (2011) 0.85
Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol (2011) 0.84
Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol (2006) 0.84
Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment. J Toxicol Environ Health A (2010) 0.84
Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. Inhal Toxicol (2008) 0.84
Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse. Environ Health Perspect (2014) 0.84
Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul Toxicol Pharmacol (2006) 0.83
Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol (2002) 0.83
In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. Toxicol In Vitro (2011) 0.83
Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. J Toxicol Environ Health A (2008) 0.83
Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. Environ Health Perspect (2014) 0.82
Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul Toxicol Pharmacol (2011) 0.82
Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal Toxicol (2003) 0.82
Evaluation of gene expression changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites. Environ Mol Mutagen (2012) 0.81
In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. Toxicol In Vitro (2013) 0.81
Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. J Toxicol Environ Health A (2007) 0.81
Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol (2011) 0.81
Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide. Regul Toxicol Pharmacol (2008) 0.81
Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. Regul Toxicol Pharmacol (2011) 0.81
Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal (2007) 0.81
Evaluation of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. Regul Toxicol Pharmacol (2008) 0.80
Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment. J Toxicol (2012) 0.80
Efficacy of predictive modeling as a scientific criterion in dermal hazard identification for assignment of skin notations. Regul Toxicol Pharmacol (2011) 0.80
Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. J Toxicol Environ Health A (2007) 0.80
Lactational transfer of manganese in rats: predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. Toxicol Sci (2009) 0.80
How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review. Toxicol Appl Pharmacol (2008) 0.80
Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal (2007) 0.80
A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A (2007) 0.80
Carcinogen biomonitoring in human exposures and laboratory research: validation and application to human occupational exposures. Toxicol Lett (2002) 0.80
Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. J Toxicol Environ Health A (2007) 0.79
Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhal Toxicol (2002) 0.79
Scientific criteria used for the development of occupational exposure limits for metals and other mining-related chemicals. Regul Toxicol Pharmacol (2002) 0.79
Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regul Toxicol Pharmacol (2005) 0.79
Effects of endogenous formaldehyde in nasal tissues on inhaled formaldehyde dosimetry predictions in the rat, monkey, and human nasal passages. Toxicol Sci (2014) 0.78
Cumulative Risk Assessment (CRA): transforming the way we assess health risks. Environ Sci Technol (2012) 0.78
Physiologically based pharmacokinetic/toxicokinetic modeling. Methods Mol Biol (2012) 0.78
Data considerations for regulation of water contaminants. Toxicology (2006) 0.78
A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry. Inhal Toxicol (2014) 0.77
Comment on M.V. Evans and J.C. Caldwell: evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice, Toxicol. Appl. Pharmacol., 244, 280-290, 2010. Toxicol Appl Pharmacol (2010) 0.77
Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. J Toxicol Environ Health A (2003) 0.77
A Bayesian network model for biomarker-based dose response. Risk Anal (2010) 0.77
Predicting passive and active tissue:plasma partition coefficients: interindividual and interspecies variability. J Pharm Sci (2014) 0.77
Derived Reference Doses (RfDs) for the environmental degradates of the herbicides alachlor and acetochlor: results of an independent expert panel deliberation. Regul Toxicol Pharmacol (2010) 0.77
Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. Toxicol Sci (2008) 0.77
Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. Regul Toxicol Pharmacol (2010) 0.77
Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. Tissue Eng Part C Methods (2014) 0.77
A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab Dispos (2011) 0.76
Derivation of inhalation toxicity reference values for propylene oxide using mode of action analysis: example of a threshold carcinogen. Crit Rev Toxicol (2009) 0.76